Preparation and Characterization of Mucoadhesive Microcapsules of Gliclazide with Natural Gums
Gliclazide is an oral hypoglycemic agent used in management of non-insulin dependent diabetes mellitus. Among people who are suffering from long term disorders, the major were categorized under diabetes so, a dosage form is needed to provide continuous therapy with high margin of safety & such dosage form can be achieved by microencapsulation. Gliclazide microspheres with sodium alginate (coat material, gum kondagogu, gum guar and xanthan gum (mucoadhesive agents) were prepared by orifice-ionic gelation and emulsification ionic gelation techniques varying concentrations (1:0.25, 1:0.5, 1:0.75 and 1:1). Formulations were then evaluated for surface morphology, particle shape, Carr’s index, microencapsulation efficiency, drug release, mucoadhesion studies. Compatibility studies were performed by FTIR, DSC, and XRD techniques and no interactions were found between drug and excepients used. The microspheres were found spherical and free flowing with emulsion ionic gelation technique with a size range 400-600μm. % drug content and encapsulation efficiency found in the range of 55%-68% and, 86.23%-94.46% respectively. All microspheres showed good mucoadhesive property in in-vitro wash of test. In vitro drug release studies showed that the guar gum has more potentiality to retard the drug release compared to other gums and concentrations. Drug release from the microspheres was found slow following zero order release kinetics with non-fickian release mechanism stating release depended on the coat: core ratio and the method employed. The concentration of 1:1 of SA: GG (EMG 4) found suitable for preparing the controlled release formulation of gliclazide stating emulsification gelation technique is the best among followed.
Key words: Gliclazide; Natural gums; orifice ionic gelation technique; emulsification ionic gelation technique
SJPS 2011; 4(1): 38-48
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.